Intra-vesical BCG induced granulomatous hepatitis and disseminated Koch’s: Our experience by Ghule, Rahul Ramdas et al.
Ghule et al                  Intra-vesical BCG induced granulomatous hepatitis  
Vol 3 Issue 1 Jan – Mar 2017                                                        Indian J Case Reports / 47 
Case Report 
Intra-vesical BCG induced granulomatous hepatitis and disseminated 
Koch’s: Our experience 
Rahul Ramdas Ghule, Subodh Ratnakar Shivde, Ram Naresh Daga 
From the Department of Urology and Andrology, Deenanath Mangeshkar Superspeciality Hospital and Research Centre, 
Pune, Maharashtra, India 
Correspondence to: Dr. Rahul Ghule Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharshtra, India. Email: 
drrahulghule@gmail.com 
Received: 10 Oct 2016    Initial Review: 02 Nov 2016    Accepted:  02 Nov 2016      Published Online: 31 Dec. 2016 
ABSTRACT 
Bacille Calmette-Guerin (BCG) vaccine, developed by Calmette and Guerin at Institute Pasteur (Lille, France), is a live-
attenuated Mycobacterium bovis strain. There are many therapeutic uses of the species have been described, Intravesical BCG 
has been established as an effective treatment of superficial bladder cancer. A 66-year old gentleman with newly diagnosed 
superficial high-grade papillary transitional cell carcinoma involving lamina propria (T1) of the bladder underwent 3 cycles of 
intravesical BCG. First 2 cycles were uneventful and tolerated well. After 3rd BCG cycle, patient developed granulomatous 
hepatitis with disseminated Koch's. BCG-induced sepsis after intra-vesical instillation for bladder cancer is a rare complication. 
Pathophysiology remains largely unknown, but BCG’s low virulence suggests that immunological hypersensitivity reaction 
probably plays a role. There have been no prospective studies to evaluate the optimal treatment for BCG infection. 
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ntravesical instillation of bacilli Calmette-Guerin 
(BCG) has been established as an effective modality 
for superficial bladder cancer. Complication of 
intravesical BCG ranges from dysuria to disseminated 
Koch’s. Complications can appear early (within 3 months 
after instillation) or years after first BCG treatment [1]. 
Early presenting disease is characterized by generalized 
symptoms, hepatitis and pneumonitis. Late presenting 
disease is usually localized, with no systemic 
manifestations and the infection involves often the 
genitourinary tract and other sites that are typical for 
reactivation of mycobacterial disease, such as the vertebral 
spine or retroperitoneal tissue [1]. Certain aspects 
concerning its diagnostic and treatment are still debatable 
[2]. We herein report 65 year male developing 
granulomatous hepatitis with disseminated Koch’s 
secondary to Intravesical BCG. 
 
CASE REPORT 
A 66-year-old gentleman with newly diagnosed superficial 
high-grade papillary transitional cell carcinoma involving 
lamina propria (T1) of the bladder underwent 3 cycles of 
intravesical BCG. First 2 cycles were uneventful and 
tolerated well. After 3
rd
 BCG cycle, patient presented with 
fever, and dysuria. Initially, he was treated as grade 1 BCG 
adverse reaction with supportive treatment. After few days 
down the line, patient presented with jaundice, on and off 
fever, joint pain, and malaise. On investigations, liver 
function test was deranged (Total serum bilirubin-
6.5mg/dl, indirect component-3.8, SGPT-650U, SGOT-
540U, Alkaline phosphatase-170IU/L) and had leukopenia 
(WBC-2100) routine aerobic urine culture and blood 
culture did not yield any pathogen. Chest X-ray was 
unremarkable. Ultrasonography of abdomen suggestive of 
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hepatomegaly with altered ecotexture of liver parenchyma. 
Patient underwent Contrast Enhanced CT scan of 
Abdomen and pelvis; suggest hepatomegaly, 
heterogeneous liver parenchyma with gall bladder edema. 
In view of deranged LFT and CT scan findings, CT 
guided liver biopsy was performed which showed 
granulomatous hepatitis with non-caseating granuloma 
(fig. 1) suggestive of tubercular etiology. Worsening 
pancytopenia prompted a bone marrow biopsy that 
revealed multiple large noncaesating granulomas. 
 
Fig 1: liver biopsy showing granulomatous hepatitis With 
multinucleate giant cell epitheloid granuloma 
Liver biopsy tissue and bone marrow biopsy tissue 
also sent for AFB culture and TB PCR. TBPCR was 
negative. AFB cultures were also negative after 8 weeks of 
incubation (BD MGIT 320 TB SYSTEM). In view of 
biopsy report, patient was put on anti-koch’s therapy for 6 
month (Isoniazid 5mg/kg/day; pyrazinamide 50mg/kg/day; 
ethambutol 15mg/kg/day) and short course of 
corticosteroid (prednisolone 20mg twice a day and tapered 
gradually). Patient gradually improved and his fever 
subsided within several day of anti-tuberculosis therapy. 
DISCUSSION 
The intravesical administration of BCG has become 
modality of treatment for superficial bladder cancer [3, 4]. 
Bacille Calmett-Guerin (BCG) is a low virulence 
mycobacteria originated from successive culture of 
mycobacterium bovis [5]. Initially BCG was used to 
vaccinate the cattle to prevent tuberculosis and later used 
in humans [1]. 
Mechanism of action of BCG in bladder cancer is 
largely unknown and probably is specific anti-BCG cell 
mediated immunity, inducing the production of large 
amounts of cytokines that draw cytotoxic activity by 
natural killer cells against transitional cancer cells [6]. The 
pathogenic mechanism underlying the development of 
complications is unclear, but BCG’s low virulence 
suggests that immunological hypersensitivity reaction 
probably plays a role. Complication ranges from lower 
urinary tract symptoms (LUTS) to organ involvement and 
disseminated infection. Localized and late infection can 
involve bone, muscle, vessels (aneurysms and 
pseudoaneurysm), eyes (granulomatous anterior uveitis, 
endophthalmitis, and autoimmune retinopathy) and 
genitourinary tract (cystitis, sterile pyuria, nephritis and 
epididymo-orchitis) [7-9]. Diagnosis of BCG related sepsis 
frequently challenging since symptoms are indistinct from 
the other causes of sepsis like bacteremia, urinary tract 
infections, respiratory infections (pneumonia), viral 
hepatitis, etc. 
Pre-existing cystitis or persistent hematuria following 
transurethral resection of bladder tumor is main 
predisposing factor [8]. Lamm et al. [10] have suggested 
that fever or shivering during or shortly after BCG 
intravesical instillation may be predictive for the risk of 
developing severe infection. Previous tuberculosis or latent 
tuberculosis infections do not seem to be higher risk of 
BCG complications [1]. It is known that diabetic patient 
have greater risk of developing tuberculosis and that poor 
glycemic control is associated with complication from 
intravesical BCG [1]. Quanti FERON-TB Gold test 
positivity only indicates previous contact with 
Mycobacterium tuberculosis and it is not useful for 
diagnosis of BCG complications. Staining of specimens 
for acid-fast bacilli, cultures and PCR testing for 
mycobacterial DNA should be performed in any patient 
with suspected disseminated BCG infection, even though 
all of these procedures can be negative in some cases. 
Concurrent prophylactic use of isoniazid with 
intravesical instillation has largely been unsuccessful. On 
the contrary, prophylactic use of fluroquinolones may be 
more effective [11, 12]. Some authors recommend 
screening with Mantoux test. Active tuberculosis has to be 
ruled out. Use of corticosteroid is convincing in early 
course of therapy. 
CONCLUSION 
Post intravesical BCG complication and adverse reactions 
has wide range of presentation from dysuria to 
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disseminated sepsis. Even initial cycles were well 
tolerated; subsequent dosage can leads to complications. 
Usually the symptomatology is nonspecific, hence need 
high index of suspicion for the diagnosis and to prevent 
further complications. Systemic 3 drug anti-tuberculous 
therapy has well proven role in literature for post BCG 
sepsis. 
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